Recombinant Rat Meprin A subunit beta (Mep1b)

What is the domain structure of Meprin beta subunit?

Meprin beta subunit (MEP1B) contains multiple functional domains arranged in a specific sequence. The 701 amino acid sequence of human Meprin beta subunit precursor consists of:

• Signal peptide (residues 1-21)

• Pro region (residues 22-61)

• Mature chain (residues 62-701) containing:

  • Catalytic domain (residues 62-259) with zinc-binding active site motif HExxHxxGxxH/N

  • MAM (meprin A5 protein tyrosine phosphatase μ) domain (residues 260-429)

  • MATH (meprin-and-TRAF homology) domain (residues 430-585)

  • Intervening domain (AM domain)

  • EGF-like domain (residues 604-644)

  • Transmembrane domain (residues 653-673)

  • Cytoplasmic domain (residues 674-701)

The catalytic domain contains the essential zinc-binding motif that forms the active site of this metalloprotease. The conserved methionine-containing β-hairpin (Met turn) is a distinctive structural feature of this enzyme family .

How does Meprin beta differ from Meprin alpha in structural organization?

While Meprin alpha and beta subunits share approximately 42% amino acid sequence identity, they exhibit significant differences in:

• Oligomeric structure: Meprin A consists of homo-oligomeric alpha subunits or hetero-oligomeric alpha and beta subunits, while Meprin B consists exclusively of homo-oligomeric beta subunits .

• Post-translational processing: Both subunits are initially synthesized as proteins containing transmembrane domains, but during biosynthesis, the membrane-spanning domain of the alpha subunit is proteolytically cleaved. In contrast, the beta subunit retains its intact transmembrane domain .

• Cellular localization: The beta subunit with its intact transmembrane domain is anchored to the brush-border membrane as a type 1 integral plasma membrane protein, while the alpha subunit can be secreted .

• Substrate specificity: They differ significantly in substrate recognition and peptide bond specificity. After trypsin treatment, activated Meprin beta preferentially cleaves peptides containing Asp and Glu at the P1' and P1 sites .

• Active site composition: Meprin alpha has Gln215 instead of Ser212 (Meprin beta) and Phe217 instead of Thr214 (Meprin beta), which alters the S1'-pocket structure and affects inhibitor binding properties .

Where is Meprin beta primarily expressed in mammalian tissues?

Meprin beta is primarily expressed in the apical membranes of renal proximal tubules as an integral membrane protein . Using subunit-specific antibodies, researchers have demonstrated colocalization of both Meprin alpha and beta in the apical membranes of mouse proximal tubules. These antibodies did not detect staining in the luminal surface of distal tubules, glomeruli, or collecting ducts, indicating that Meprin beta expression is restricted exclusively to the brush-border membranes of proximal tubules .

Beyond the kidney, Meprin beta is known to cleave cell-adhesion molecules in various tissues including:

• Skin

• Intestine

• Brain endothelium

This tissue-specific expression pattern makes Meprin beta particularly important in barrier function across multiple organ systems.

What are the recommended methods for generating Meprin beta overexpressing cell lines?

Based on published protocols, researchers can generate stably overexpressing Meprin beta cell lines using retroviral transduction. A detailed methodology includes:

• Packaging cell preparation:

  • Transfect packaging cells (e.g., GP-293) with a pLBCX Mep1b construct using polyethylenimine (PEI)

  • Change medium 6 hours post-transfection

  • Collect virus-containing medium for 24 hours

• Target cell infection:

  • Infect target cells (e.g., bEnd.3 brain endothelial cells) with the collected virus

  • Include 40 μg/mL polybrene during the 24-hour infection period

  • Select infected cells with 5 μg/mL blasticidin for two weeks

• Clone selection and culture:

  • Isolate and expand clones with high expression of Mep1b

  • Seed 50,000 cells per cm² for experimental use

  • Perform experiments five days after seeding when cells have reached confluency

This protocol has been successfully implemented to study Meprin beta's effects on tight junction proteins and blood-brain barrier integrity.

How should recombinant Meprin beta be stored and handled to maintain optimal activity?

Proper storage and handling of recombinant Meprin beta is critical for maintaining enzymatic activity:

The purified recombinant protein should be aliquoted upon receipt to minimize freeze-thaw cycles. For carrier-free preparations, BSA is not included, which makes these formulations particularly suitable for applications where the presence of BSA could interfere with experimental outcomes .

What assays can be used to measure Meprin beta enzymatic activity?

Several methodologies have been developed to assess Meprin beta enzymatic activity:

• Fluorogenic peptide substrates:

  • Use peptides containing Asp and Glu at the P1' and P1 sites (preferred cleavage sites)

  • Measure activity with fluorescence detection following substrate cleavage

  • Typical specific activity for recombinant human MEP1B is >350 pmol/min/μg under standard conditions

• Zymography:

  • Useful for visualizing protease activity in gel systems

  • Has been applied in publications studying Meprin properties

• Bioassays:

  • Functional assays measuring biological effects of enzymatic activity

  • Applied in research examining physiological substrates

• Inhibitor screening:

  • Hydroxamate-based inhibitors can be used to assess Meprin beta activity

  • IC₅₀ values can be determined to compare selective inhibition between Meprin alpha and beta

How does Meprin beta influence blood-brain barrier integrity?

Recent research has identified Meprin beta as a novel regulator of blood-brain barrier (BBB) integrity. In studies using Mep1b-transfected mouse brain endothelial cells (bEnd.3), researchers observed:

• Tight junction protein alterations:

  • Reduction of the tight junction protein claudin-5

  • Changes in tight junction composition affecting barrier function

• Functional barrier changes:

  • Decreased transendothelial electrical resistance (TEER)

  • Elevated permeability to paracellular diffusion markers

These findings suggest that Meprin beta plays a critical role in regulating endothelial barrier function through proteolytic modulation of tight junction proteins. This mechanism may be particularly relevant for understanding BBB dysfunction in neurological disorders .

What structural insights have been gained from crystallographic studies of Meprin beta in complex with inhibitors?

Crystallographic studies have provided valuable insights into Meprin beta structure and substrate recognition:

• Active site configuration:

  • The first structure of a Meprin β holoenzyme containing a zinc ion and a specific inhibitor bound to the active site has been determined

  • The inhibitor binds in two different conformations in chain A, differing by rotation around the single bond between C17 and C18

  • Each conformation is occupied by approximately 50%

  • In chain B, only one conformation was observed, corresponding to conformation A in chain A

• Conformational changes:

  • Binding of inhibitors induces significant conformational changes in the enzyme

  • Arg184, which normally juts directly into the active site cleft in unbound Meprin β, is shifted more than 5 Å out of the active site upon inhibitor binding

  • This structural rearrangement leads to increased opening of the active site cleft

• Subdomain dynamics:

  • The NTS and CTS subdomains display different relative orientations depending on the binding state (unbound, inhibitor-bound, or pro-peptide-bound)

  • The connection between these subdomains (Phe160-Trp161) appears to function as a hinge region

  • High flexibility was observed in the three-turn region spanning Lys213-Gly219 and Trp177-Phe

• Selective inhibition:

  • Hydrogen bonding networks contribute to inhibitor affinity and selectivity

  • In Meprin beta, Ser212 and Thr214 form hydrogen bonds with the inhibitor

  • In Meprin alpha, these residues are replaced by Gln215 and Phe217, which narrows the S1'-pocket sterically and prevents formation of the hydrogen bond network

  • This structural difference explains the decreased inhibitory potency of certain compounds against Meprin alpha (IC₅₀= 16,050 ± 212 nM)

What is the role of Meprin beta in disease pathologies?

Meprin beta has been implicated in several pathological conditions associated with barrier dysfunction:

• Neurological disorders:

  • Alzheimer's disease - Meprin beta contributes to altered BBB function

  • The enzyme's ability to cleave cell adhesion molecules may contribute to neuroinflammatory processes

• Renal pathologies:

  • Acute kidney injury - Meprin A (including beta subunits) plays a significant role

  • Kidney barrier disruption is associated with altered Meprin activity

• Gastrointestinal disorders:

  • Inflammatory bowel disease - Meprin beta dysregulation has been observed

  • Intestinal barrier dysfunction may be mediated by Meprin-dependent proteolysis of junction proteins

• Pulmonary disorders:

  • Lung fibrosis - Meprin alpha (related to Meprin beta) contributes to collagen deposition

  • This suggests potential roles for Meprin family proteins in fibrotic processes

These disease associations highlight the importance of Meprin beta as a therapeutic target and the value of selective inhibitors for potential treatment approaches.

What factors could influence the activation of recombinant pro-Meprin beta in experimental settings?

Recombinant Meprin beta is typically expressed as a pro-enzyme that requires activation. Several factors may influence this activation process:

• Proteolytic processing:

  • Trypsin treatment has been shown to effectively activate the pro-enzyme

  • The pro region (residues 22-61 in human Meprin beta) must be cleaved for activation

• Expression systems:

  • The choice of expression system can affect proper folding and post-translational modifications

  • E. coli-expressed protein may have different activation properties than mammalian cell-expressed protein

• Buffer conditions:

  • pH, ionic strength, and presence of divalent cations can significantly impact activation efficiency

  • Zinc availability is critical as Meprin beta is a zinc-dependent metalloprotease

• Storage considerations:

  • Degradation during storage may affect activation potential

  • Glycerol in storage buffers helps maintain protein stability

Researchers should optimize activation conditions based on their specific experimental setup and intended applications.

How can specificity be ensured when studying Meprin beta in complex biological systems?

Ensuring specificity when studying Meprin beta requires multiple complementary approaches:

• Subunit-specific antibodies:

  • Utilize antibodies that specifically recognize Meprin beta without cross-reactivity to alpha subunits

  • These have been successfully employed to demonstrate subunit-specific localization in kidney tissues

• Selective inhibitors:

  • Take advantage of structural differences in the active sites between Meprin alpha and beta

  • Hydroxamate-based inhibitors show differential potency against the two subunits

• Genetic approaches:

  • Use of knockout models or siRNA-mediated knockdown provides specificity

  • Complementary overexpression studies in appropriate cell models

• Substrate specificity:

  • Design assays using substrates with preference for Meprin beta over alpha

  • Consider the preference for Asp and Glu at the P1' and P1 sites in Meprin beta

• Careful experimental controls:

  • Include controls for non-specific proteolysis

  • Compare wild-type and catalytically inactive mutants to distinguish enzymatic from scaffold functions

What emerging applications of recombinant Meprin beta are being explored in cell biology research?

Several innovative research directions are emerging for recombinant Meprin beta:

• Blood-brain barrier modulation:

  • Controlled manipulation of BBB permeability for drug delivery

  • Research into mechanisms of BBB dysfunction in neurodegenerative diseases

• Extracellular matrix remodeling:

  • Meprin beta's role in collagen processing and matrix organization

  • Implications for tissue regeneration and fibrosis

• Cell adhesion biology:

  • Proteolytic processing of cell adhesion molecules

  • Impact on cell migration, tissue architecture, and barrier function

• Signaling pathway regulation:

  • Meprin beta's potential role in processing signaling molecules

  • Cross-talk with growth factor and cytokine networks

• Development of targeted inhibitors:

  • Structure-based design of selective Meprin beta inhibitors

  • Therapeutic applications in barrier dysfunction disorders

These emerging areas represent promising directions for researchers to explore the multifaceted roles of Meprin beta in cellular processes and disease states.

How might recombinant Meprin beta be utilized in studying the pathophysiology of barrier dysfunction across different organ systems?

Recombinant Meprin beta offers valuable research tools for investigating barrier dysfunction:

• Comparative barrier studies:

  • Parallel investigation of Meprin beta effects on epithelial and endothelial barriers

  • Comparison of kidney, intestine, and blood-brain barrier responses to Meprin beta activity

• Disease modeling:

  • Development of in vitro models of barrier dysfunction using controlled Meprin beta expression

  • Application to inflammatory bowel disease, acute kidney injury, and neuroinflammatory conditions

• Substrate identification:

  • Proteomic approaches to identify tissue-specific Meprin beta substrates

  • Focus on junction proteins, basement membrane components, and cell adhesion molecules

• Mechanistic investigations:

  • Detailed study of how Meprin beta cleavage alters barrier protein functions

  • Integration of structural biology, cell biology, and physiology approaches

• Therapeutic intervention:

  • Testing of selective Meprin beta inhibitors as potential barrier-protective agents

  • Exploration of targeted delivery approaches for organ-specific barrier protection

By applying recombinant Meprin beta across these research contexts, investigators can develop a more comprehensive understanding of barrier regulation in health and disease.